
Keywords: antineoplastic agents, hormonal; costs and cost analysis; prostatic neoplasms; neoplasm metastasis; orchiectomy; ADT; androgen deprivation therapy; BSO; bilateral simple orchiectomy; ESO; epididymal sparing orchiectomy; LHRH; luteinizing hormone-releasing